ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antibodies"

  • Abstract Number: 390 • 2018 ACR/ARHP Annual Meeting

    Severe Axial and Pelvifemoral Muscle Damage in Immune-Mediated Necrotizing Myopathy Evaluated By Whole-Body MRI

    Océane Landon-Cardinal1, Cedi Koumako2, Giulia Hardouin3, Benjamin Granger3, Harmen Reyngoudt2, Jean-Marc Boisserie2, Aude Rigolet1, Baptiste Hervier1, Nicolas Champtiaux1, Perrine Guillaume1, Mathieu Vautier1, Pierre Carlier2, Olivier Benveniste1 and Yves Allenbach1, 1Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, 2Laboratoire de RMN AIM & CEA, Centre d'Explorations Fonctionnelles, Institut de Myologie, Paris, France, 3Département de Biostatistiques, Santé Publique et Information Médicale, Groupe hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) are a severe condition with early muscle damage attested by MRI of thigh muscles. Presence of damage in the other…
  • Abstract Number: 2801 • 2018 ACR/ARHP Annual Meeting

    A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis

    Kazuhiko Higashioka1, Masahiro Ayano1, Yasutaka Kimoto2, Hiroki Mitoma1, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horiuchi3 and Hiroaki Niro4, 1Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 4Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    Background/Purpose: A plethora of evidence from genome-wide association studies and relevant animal models implicates a pivotal role of T cells in the pathogenesis of rheumatoid…
  • Abstract Number: 397 • 2018 ACR/ARHP Annual Meeting

    Myositis-Specific Autoantibodies and Their Clinical Associations

    Victor Tak Lung Wong1, Ho So1, Ricky Wai Ki Ip2, Virginia W Lao3, Steve H Pang3, Lai-Shan Tam4, Priscilla Wong5, Lydia Ho Pui Tam6, Tsz On Lam7, Mei Yan Law8, Isaac CW Yim9, Tin Lok LAI10, Patrick Man Leung Lee11 and Ronald Man Lung Yip12, 1Kwong Wah Hospital, Kowloon, Hong Kong, 2Queen Mary Hospital, Hong Kong, Hong Kong, 3Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, 4Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, 5Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, 6Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 7Prince of Wales Hospital, New Territories, Hong Kong, 8Alice Ho Miu Ling Nethersole Hospital, New Territories, Hong Kong, 9Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, 10Medicine, Tseung Kwan O Hospital, Tseung Kwan O, Hong Kong, 11Yan Chai Hospital, Kowloon, Hong Kong, 12Tung Wah Group of Hospitals, Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Myositis-specific autoantibodies (MSAs) have been shown to predict clinical features and have prognostic implications in patients with idiopathic inflammatory myopathies (IIMs), with anti-melanoma differentiation-associated…
  • Abstract Number: 2935 • 2018 ACR/ARHP Annual Meeting

    A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification

    Svetlana I. Nihtyanova1, Emma C. Derrett-Smith2, Carmen Maria Fonseca3, Voon H. Ong2 and Christopher P. Denton4, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Division of Medicine, University College London, London, United Kingdom, 3Department of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 4University College London, London, United Kingdom

    Background/Purpose: The Le Roy et al. classification of SSc into limited and diffuse cutaneous subtype remains the most commonly used. Nevertheless, autoantibodies are much better…
  • Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting

    Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial

    Guro Løvik Goll1, Nils Bolstad2, Ines Iria3,4, Rolf Klaasen5, Kristin Kaasen Jørgensen6, Inge C Olsen7, Ana Valido8, Maria J Saavedra9, João E. Fonseca10, Merete Lorentzen11, Cato Mork12, Knut EA Lundin13, David J Warren14, Espen A. Haavardsholm15, Jorgen Jahnsen16, Tore Kvien15 and João Gonçalves17, 1Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 3Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, 4iMed- Research Institute for medicines, Lisbon, Portugal, 5Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 6Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 7Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 9Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, 10Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 11Dept of Dermatology, Rikshospitalet, Oslo, Norway, 12Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 13Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, 14Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 15Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 16Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 17Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal

    Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
  • Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting

    NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis

    Ana Paula Luppino-Assad1, Adriana Bortoluzzo2, Henrique Carriço da Silva3, Danieli Andrade4 and Percival Sampaio-Barros4, 1Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, 2c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, 3Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, 4Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil

    Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
  • Abstract Number: 999 • 2018 ACR/ARHP Annual Meeting

    Development of an Affimab Engineered to Simultaneously Target IL-6 and Tnfα for Therapeutic Use in Rheumatoid Arthritis

    Kyu-Tae Kim, Jong-Seo Lee and Bong-Kook Ko, AbClon Inc., Seoul, Korea, Republic of (South)

    Background/Purpose: Antibodies may be functionalized using Affibody® molecules to create bispecific AffiMabs. We used protein engineering to develop single-construct biologics suitable for blocking inflammation driven…
  • Abstract Number: 1223 • 2018 ACR/ARHP Annual Meeting

    Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis

    Caitlyn L. Holmes1, Chloe Peyton2, Amy Bier3, Tobias Donlon2, Christie M. Bartels4 and Miriam A. Shelef5,6, 1University of Wisconsin - Madison, Madison, WI, 2University of Minnesota Medical School, Minneapolis, MN, 3Stritch School of Medicine of Loyola University Chicago, Chicago, IL, 4Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, 5Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, 6William S. Middleton Memorial Veterans Hospital, Madison, WI

    Background/Purpose: Patients with rheumatoid arthritis, an autoimmune disease affecting ~1% of the population, have an increased risk of infection. Interestingly, data are mixed for response…
  • Abstract Number: 1310 • 2018 ACR/ARHP Annual Meeting

    Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease

    Verónica Wolff1, Juan Maya2, Carolina Cuéllar3, Matías Florenzano1, Alexis Peralta4 and Viviana Balboa4, 1Rheumatic Lung diseases Unit, Instituto Nacional del Tórax, Santiago, Chile, 2Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, 3Rheumatology Section, Hospital del Salvador, Universidad de Chile, SANTIAGO, Chile, 4Laboratorio Inmunología, Hospital Del Salvador, SANTIAGO, Chile

     Background/Purpose: Interstitial Lung Disease (ILD) is a common manifestation of  Connective Tissue Diseases (CTD), mainly Systemic sclerosis (SSc), Rheumatoid Arthritis and Idiopathic Inflammatory Myositis (IIM)…
  • Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting

    Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A

    Fang Shen1, Jennifer F. Nemeth2, Brian Jones1, Ann Cai1, Shannon Hitchcock3, Thai Dinh2, Ravi Malaviya1 and Tatiana Ort1, 1Immunology, Janssen R&D, Spring House, PA, 2Janssen Biotech, Janssen R&D, Spring House, PA, 3Immunology, Janssen R&D, Springhouse, PA

    Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…
  • Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting

    Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells

    Ash Maroof1, Remi Okoye1, Tim Smallie1, Dominique Baeten2,3, Sophie Archer1, Catherine Simpson1, Meryn Griffiths1 and Stevan Shaw1, 1UCB Pharma, Slough, United Kingdom, 2UCB Pharma, Brussels, Belgium, 3University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
  • Abstract Number: 1666 • 2017 ACR/ARHP Annual Meeting

    Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations

    Yann Becker1, Renee Claude Loignon1, Genevieve Marcoux1, Anne-Sophie Julien2, Imene Melki1, Lihi Eder3, Eric Wagner1, Martin Pelletier1, Marie-Josee Hebert4, Clemence Belleannee1, Joyce Rauch5, Melanie Dieude4, Paul R. Fortin6 and Eric Boilard1, 1CHU de Quebec and Universite Laval, Quebec City, QC, Canada, 2CHU de Quebec - Universite Laval, Quebec City, QC, Canada, 3Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, 4CHUM and Universite de Montreal, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada

    -          Background/Purpose: Eukaryotic cells contain organelles called mitochondria that govern energy supply and control of cell death. Whereas damaged organs or activated cells can extrude…
  • Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting

    Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies

    Earl Sands1, Alan J. Kivitz2, Wesley DeHaan Ph.D.1, Lloyd Johnston1 and Takashi Kei Kishimoto1, 1Selecta Biosciences, Watertown, MA, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose:   Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
  • Abstract Number: 2136 • 2017 ACR/ARHP Annual Meeting

    Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis

    Adam Schiffenbauer1, Sara Faghihi-Kashani2, Terrance P. O'Hanlon1, Willy Flegel3, Sharon Adams3, Ira N. Targoff4, Chester V. Oddis5,6, Rohit Aggarwal7,8, Lisa G Rider1, Steven R. Ytterberg9, Lisa Christopher-Stine10, Sonye K. Danoff11, Paul F. Dellaripa12,13, Ejaz Shamim14, Andrew Mammen15 and Frederick W Miller16, 1Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 2Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, 3Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, 4VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, 6Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, 8Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, 9Rheumatology, Mayo Clinic, Rochester, MN, 10Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 11Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, 12Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 13Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, 149. Department of Neurology, Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, 15Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, 16Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication and a major contributor to mortality and morbidity in polymyositis and dermatomyositis (PM/DM). Prior studies have…
  • Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting

    Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis

    Eri Watanabe1, Takahisa gono1, Shinji Watanabe1, Hiroki Yabe1, Masataka Kuwana2 and Chihiro Terai1, 1Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology